Compounded Tesamorelin
Check whether compounded Tesamorelin can be routed, what restrictions may apply, and what to ask your prescriber or pharmacist.
About Tesamorelin
Important: Tesamorelin is not currently eligible for compounding by licensed U.S. pharmacies due to FDA restrictions. Quote requests for Tesamorelin cannot be fulfilled through Compounding Finder.
Key Questions Before You Request Quotes
Can I get Tesamorelin compounded?
Not through Compounding Finder right now. A prescriber and pharmacist still have to decide whether any compounded Tesamorelin preparation is legally and clinically appropriate.
Is a prescription needed?
Yes. Patient-specific 503A compounding is based on a valid prescription order or prescriber notation for an identified patient.
What affects price?
Strength, dosage form, quantity, ingredient sourcing, sterile versus non-sterile preparation, shipping requirements, and each pharmacy's workflow can all change the final quote.
How fast can I get quotes?
For routable requests, Compounding Finder typically returns quote options by email within 1-2 business days after you submit the request details.
What happens after I submit?
We review the request, route it to eligible licensed pharmacies, collect available options, and email you the quoted choices. You decide whether to move forward with a pharmacy.
Source notes: FDA explains that compounded drugs are not FDA-approved finished products and describes 503A compounding around patient-specific prescriptions. See Compounding and the FDA and Section 503A.
We Do Not Currently Route Tesamorelin Quote Requests
Tesamorelin (Egrifta) is FDA-approved only for HIV-associated lipodystrophy and is not available for compounded off-label use through our network. If FDA guidance changes, we will revisit.